Search

New findings by researchers at MSK and their collaborators at the Icahn School of Medicine point to an opportunity to improve therapies that use small RNAs to silence disease-causing genes, potentially including those involved in cancer.

… Friday, December 20, 2024 In everyday life, when things turn out the opposite of what you expect, it’s usually cause for frustration. In science, it’s often the starting point for discovery. That’s what happened to a team of researchers from Memorial Sloan Kettering Cancer Center (MSK) and their collaborators

MSK investigators are leading research focused on understanding how hereditary DNA mutations affect cancer development and therapy, and how to best treat people who carry these inherited risks in their genes.

… Monday, June 5, 2023 Researchers from Memorial Sloan Kettering Cancer Center (MSK) revealed new findings about hereditary cancers and genetics at the recent 2023 American Society of Clinical Oncology (ASCO) annual meeting. Genetic mutations that are passed down through families cause a significant percentage

Patients with primary gastrointestinal stromal tumor, a type of tumor found in the stomach or small intestine, who received imatinib (Gleevec ®) after complete removal of their tumor were significantly less likely to have a recurrence of the cancer compared to those who did not receive imatinib.

… Thursday, April 12, 2007 Memorial Sloan Kettering Cancer Center’s Ronald DeMatteo, MD, served as the principal investigator of a large cooperative group trial that found patients with primary gastrointestinal stromal tumor, a type of tumor found in the stomach or small intestine, who received imatinib

Researchers have identified a set of genetic abnormalities in patients with acute myelogenous leukemia (AML) that doctors can use to more accurately predict patients’ prognoses and select treatments that are most likely to benefit them. The study, led by investigators at Memorial Sloan Kettering Cancer Center, will be published in the March 22 issue of the New England Journal of Medicine.

… Wednesday, March 14, 2012 Researchers have identified a set of genetic abnormalities in patients with acute myelogenous leukemia (AML) that doctors can use to more accurately predict patients’ prognoses and select treatments that are most likely to benefit them. The study, led by investigators at Memorial

Memorial Sloan Kettering Cancer Center (MSK) executives, including longtime board member David Koch, along with construction workers and physicians will all gather today for a “topping off” ceremony to mark completion of the steel construction phase of the David H. Koch Center for Cancer Care. The 750,000-square-foot, 23-story outpatient cancer center on East 74th Street and FDR Drive is made possible by a landmark gift of $150 million from Mr. Koch, the largest single gift in the history of the institution.

… Thursday, May 11, 2017 Memorial Sloan Kettering Cancer Center (MSK) executives, including longtime board member David Koch, along with construction workers and physicians will all gather today for a “topping off” ceremony to mark completion of the steel construction phase of the David H. Koch Center

Active surveillance of prostate cancer is being increasingly utilized for men with low-risk cancer. But some men with potentially life-threatening cancers are being inadvertently enrolled in such programs, driving the need for more accurate decision-making tools such as the 4Kscore test developed at Memorial Sloan Kettering.

… Thursday, October 12, 2017 Active surveillance of prostate cancer is being increasingly utilized for men with low-risk cancer. But some men with potentially life-threatening cancers are being inadvertently enrolled in active surveillance programs, driving the need for more-accurate decision-making tools

The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan Kettering Cancer Center.

… Wednesday, February 13, 2013 The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan Kettering Cancer Center. Published in the February

In order to preserve healthcare resources and provide exceptional care, our teams have been working together to develop new and innovative ways to treat our patients during the COVID-19 pandemic. MSK radiation oncologists rapidly re-evaluated our rectal cancer practice policies during this public health emergency.

… Friday, May 15, 2020 Cancer care is essential and should not be put on hold. Here at Memorial Sloan Kettering (MSK) we’ve put in place the strictest safety measures to ensure our patients continue to receive world-class cancer care in the safest environment possible. In order to preserve healthcare resources

Spinal cord compression due to spinal metastases is a medical emergency. Modern treatment approaches have fundamentally shifted the paradigm from providing short-term palliation and pain relief to delivering durable tumor control with fewer morbidities than older approaches. Therefore, cancer patients who have symptoms of spinal cord compression should be referred for surgical evaluation as soon as possible.

… Thursday, June 14, 2018 Spinal cord compression due to spinal metastases is a medical emergency. Modern treatment approaches — minimally invasive surgical techniques and spinal stereotactic radiosurgery (SSRS) — have fundamentally shifted the paradigm from providing short-term palliation and pain relief

The test, developed at MSK, looks for alterations in 468 genes that are seen in both common and rare cancers.

… Wednesday, November 15, 2017 Summary The FDA’s authorization of MSK-IMPACT sets a precedent for future authorization of tests developed by both academic and commercial labs. The US Food and Drug Administration has announced the authorization of MSK-IMPACT™ . The test was developed by Memorial Sloan Kettering